Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

746
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
746
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

511
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
511

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Caregiver Reports of Lucid Episodes in Alzheimer's Dementia and Lewy Body Dementias.

Journal of geriatric psychiatry and neurology·2026
Same author

Combining post-mortem and neuroimaging measures of brain amyloidosis to accelerate genomic discovery.

Brain : a journal of neurology·2026
Same author

Variability in Clinical Performance of the FDA-Cleared Lumipulse P-Tau217/β-Amyloid 1-42 Plasma Ratio.

JAMA neurology·2026
Same author

Remote, unsupervised assessment of cognitive impairment and decline in Alzheimer's disease using the Cogstate Brief Battery in ADNI-3.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Identification and quantification of Hypocretin-1/Orexin-A 1-14 and 1-16 fragments in immunopurified cerebrospinal fluid using LC-MS: Comparison with radioimmunoassay (RIA) determinations.

Sleep medicine·2026
Same author

Health system patterns of imaging and fluid biomarker testing in the era of anti-amyloid therapies.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Breaking barriers: Enhancing access to dementia clinical trials in the United Kingdom-Insights from the Scientific Advisory Board of the Dame Barbara Windsor Dementia Goals Programme.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Susan Ashrafzadeh-Kian1, Joshua A Bornhorst1, Daniel Figdore1

  • 1Mayo Clinic, Rochester, MN, USA.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 24, 2025
PubMed
Summary
This summary is machine-generated.

Alzheimer's disease (AD) blood biomarkers like GFAP and p-tau217 decreased in patients receiving lecanemab therapy. These changes suggest potential for monitoring treatment response in AD.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

Area of Science:

  • Neuroscience
  • Biomarker Research
  • Pharmacology

Background:

  • Alzheimer's disease (AD) blood biomarkers (BBMs) show promise for monitoring anti-amyloid therapies.
  • Individual-level changes in AD BBMs require further understanding for treatment monitoring.

Purpose of the Study:

  • To assess longitudinal changes in AD BBMs in patients undergoing lecanemab therapy.
  • To determine if AD BBMs can reflect treatment response and amyloid clearance.

Main Methods:

  • Longitudinal EDTA-plasma samples collected from patients receiving lecanemab.
  • Assessed p-tau217, p-tau181, GFAP, NfL, Aβ42, Aβ40, Aβ42/40, and p-tau217/Aβ42.
  • Analyzed median biomarker differences and patient groups based on biomarker changes up to 6 months.

Main Results:

  • No significant median biomarker changes at 3 months.
  • Aβ42/40 showed a significant median decrease at 6 months (p=0.0058).
  • GFAP, p-tau217, and Aβ42/40 showed the most frequent decreases (80%, 60%, 60% of patients, respectively).

Conclusions:

  • GFAP, p-tau217, and Aβ42/40 demonstrated frequent decreases post-lecanemab treatment.
  • Ongoing collection aims to correlate AD BBM changes with Amyloid PET.
  • These preliminary findings support AD BBMs' utility in monitoring lecanemab therapy.